Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer

Inclusion Criteria: * 18 years of age or older * Male or non-pregnant and non-lactating female * Histologically or cytologically confirmed adenocarcinoma of pancreas * Patients must have satisfactory blood counts and blood chemistry levels at baseline (refer to Appendix 2, Study Laboratory References Range). * Patient has Eastern Cooperative Oncology Group(ECOG) Performance Status 0 to 1 (refer to Appendix 7): * 0 - Asymptomatic (Fully active, able to carry on all predisease activities without restriction) * 1 - Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work) * Signed study consent form Exclusion Criteria: * \<18 years of age * Pregnant or lactating female * Patient has islet cell neoplasms * Patient has known brain metastases * Patient has metastatic disease * Active secondary malignancies * Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy * Known infection with hepatitis B, hepatitis C, or cirrhosis * Major surgery or vascular device placement (excluding ports for IV medication/chemotherapy) within 2 weeks prior to Day 1 of treatment in study * Prior chemotherapy or radiation for pancreatic cancer * History of allergy or hypersensitivity to the study drugs * Patient is enrolled in any outside (outside Baylor University Medical Center or Texas Oncology) clinical protocol or investigational trial * Significant cardiac disease as defined as New York Heart Association (NYHA) classification III or IV, uncontrolled congestive heart failure (CHF), or prior myocardial infarction (MI) last 6-months * Any prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation which in the opinion of the investigator may place the patient at increased risk * Peripheral sensory neuropathy ≥ to grade 2 at baseline * Significant co-morbidities deemed by investigator as unsuitable for participation/enrollment * Study consent form not signed